{"filing":{"accession_number":"0001062993-26-003338","cik":"0001833141","ticker":"HELP","company_name":"CYBIN INC.","form":"6-K","filing_date":"2026-06-24","report_date":null,"primary_document":"form6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1833141/000106299326003338/form6k.htm"},"events":[{"id":13650,"run_id":12119,"accession_number":"0001062993-26-003338","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Cybin Inc. announced an underwritten public offering of 10,309,280 common shares at US$4.85 per share for aggregate gross proceeds of US$50 million, underwritten by Cantor and Barclays, with expected closing on June 25, 2026, subject to customary closing conditions and regulatory approvals.","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-06-24","form":"6-K","submitted_at":null,"items":[{"id":10852,"accession_number":"0001062993-26-003338","item_number":"EX-99.1","item_title":"exhibit99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Helus Pharma (Cybin Inc.) announces an underwritten offering of 10,309,280 common shares at US$4.85 per share for aggregate gross proceeds of US$50 million. This is a material equity issuance that will dilute existing shareholders. The offering is underwritten by Cantor and Barclays and is expected to close on June 25, 2026, subject to customary closing conditions and regulatory approvals from Cboe Canada and Nasdaq notification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:04:42.765064+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10854,"accession_number":"0001062993-26-003338","item_number":"EX-99.3","item_title":"exhibit99-3.htm","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.25,"reasoning":"This exhibit is an underwriting agreement for the issuance of 10,309,280 common shares for aggregate gross proceeds of $50,000,008.00. While the agreement itself is a contractual document governing the terms of the offering, the substance is an equity issuance, not a debt issuance. However, the exhibit appears to be the agreement document itself rather than a discrete event announcement. The classification is uncertain because this is a contract document rather than a news release or event disclosure, and the proper classification may be `dilutive_issuance` (equity offering) rather than `debt_issuance`.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:04:42.765064+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":13651,"run_id":12119,"accession_number":"0001062993-26-003338","anchor_item_number":"EX-99.2","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Cybin announced that its APPROACH Phase 3 trial of HLP003 has surpassed 86% enrollment and remains on track for Q4 2026 topline data readout, representing material progress on a clinical-stage development program critical to the company's regulatory pathway and investor valuation.","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-06-24","form":"6-K","submitted_at":null,"items":[{"id":10853,"accession_number":"0001062993-26-003338","item_number":"EX-99.2","item_title":"exhibit99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a clinical-stage progress update announcing that the APPROACH Phase 3 trial of HLP003 has surpassed 86% enrollment and remains on track for Q4 2026 topline data readout. While the company references previously reported Phase 2 efficacy data, this is not a discrete earnings release or financial results announcement—it is an operational milestone update on a material clinical development program. The disclosure is material because Phase 3 trial progress and timelines are critical to investor assessment of a clinical-stage pharmaceutical company's value and regulatory pathway, but it does not fit the specific event types (e.g., earnings_release, which requires actual financial results). Classified as operational_other because it is a material operational/strategic milestone in drug development that does not match a named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:04:42.765064+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10852,"accession_number":"0001062993-26-003338","item_number":"EX-99.1","item_title":"exhibit99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Helus Pharma (Cybin Inc.) announces an underwritten offering of 10,309,280 common shares at US$4.85 per share for aggregate gross proceeds of US$50 million. This is a material equity issuance that will dilute existing shareholders. The offering is underwritten by Cantor and Barclays and is expected to close on June 25, 2026, subject to customary closing conditions and regulatory approvals from Cboe Canada and Nasdaq notification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:04:42.765064+00:00","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-06-24"},{"id":10853,"accession_number":"0001062993-26-003338","item_number":"EX-99.2","item_title":"exhibit99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a clinical-stage progress update announcing that the APPROACH Phase 3 trial of HLP003 has surpassed 86% enrollment and remains on track for Q4 2026 topline data readout. While the company references previously reported Phase 2 efficacy data, this is not a discrete earnings release or financial results announcement—it is an operational milestone update on a material clinical development program. The disclosure is material because Phase 3 trial progress and timelines are critical to investor assessment of a clinical-stage pharmaceutical company's value and regulatory pathway, but it does not fit the specific event types (e.g., earnings_release, which requires actual financial results). Classified as operational_other because it is a material operational/strategic milestone in drug development that does not match a named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:04:42.765064+00:00","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-06-24"},{"id":10854,"accession_number":"0001062993-26-003338","item_number":"EX-99.3","item_title":"exhibit99-3.htm","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.25,"reasoning":"This exhibit is an underwriting agreement for the issuance of 10,309,280 common shares for aggregate gross proceeds of $50,000,008.00. While the agreement itself is a contractual document governing the terms of the offering, the substance is an equity issuance, not a debt issuance. However, the exhibit appears to be the agreement document itself rather than a discrete event announcement. The classification is uncertain because this is a contract document rather than a news release or event disclosure, and the proper classification may be `dilutive_issuance` (equity offering) rather than `debt_issuance`.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:04:42.765064+00:00","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-06-24"},{"id":10855,"accession_number":"0001062993-26-003338","item_number":"EX-99.4","item_title":"exhibit99-4.htm","event_type":"periodic_report","event_domain":"periodic","is_material":false,"confidence":0.75,"reasoning":"This exhibit is a legal consent letter from counsel (Aird \u0026 Berlis LLP) authorizing reference to the firm's name and advice in a prospectus supplement filed on Form F-10. It is a routine administrative disclosure supporting a securities offering registration statement, not a discrete material event. The letter itself is a procedural artifact of the prospectus filing process rather than a substantive disclosure of financial, operational, or governance significance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:04:42.765064+00:00","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-06-24"}]}